Healthcare / Healthcare PlansNasdaqGS
$26.20
+0.64 (+2.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $185.2M · quality 77.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
71/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
34.0x
↑EV/EBITDA
25.2x
↑ROE
11.3%
↑Gross Margin
23.6%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
14.9%
FCF / Net income
3.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.29B · net income $58.5M · FCF $191.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $1.29B | $1.29B | $1.17B | $1.09B | $786.9M | $500.6M | $344.9M | — | — | — |
| Net Income | $58.5M | $58.5M | $54.3M | $62.0M | $30.4M | $65.8M | $46.5M | $-8.6M | $661000.00 | $-12.5M |
| EBITDA | $90.2M | $90.2M | $70.6M | $64.5M | $24.9M | $33.6M | $10.3M | $11.8M | $-1.6M | $-9.4M |
| EPS | 0.65 | 0.65 | 0.57 | 0.62 | 0.30 | 0.66 | 0.47 | -0.41 | 0.04 | -2.37 |
| Gross Margin | 23.6% | 23.6% | 21.7% | 21.9% | 21.3% | 22.4% | 20.3% | — | — | — |
| Operating Margin | 6.6% | 6.6% | 5.8% | 5.7% | 3.0% | 6.5% | 2.4% | — | — | — |
| Net Margin | 4.5% | 4.5% | 4.7% | 5.7% | 3.9% | 13.1% | 13.5% | — | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.05 | 0.05 | 0.05 | 0.04 | 0.02 | — | — | — | — | — |
| Current Ratio | 2.13 | 2.13 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $191.8M | $191.8M | $173.7M | $185.2M | $77.2M | $23.9M | $35.2M | $-4.5M | $1.7M | $-10.1M |
| Returns | ||||||||||
| ROE | 11.3% | 11.3% | 12.9% | 11.2% | 8.1% | 26.1% | 27.8% | -7.5% | -0.7% | 12.8% |
| Valuation | ||||||||||
| P/E | 34.03 | 34.03 | 30.88 | 58.55 | 93.87 | — | — | — | — | — |
| EV/EBITDA | 25.16 | 25.16 | 21.76 | 55.48 | 108.35 | — | — | — | — | — |
| P/B | 4.56 | 4.56 | 3.98 | 6.60 | 7.47 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 10.4% | 10.4% | 7.2% | 38.3% | — | 45.2% | — | — | — | — |
| EPS Growth | 14.0% | 14.0% | -8.1% | 106.7% | — | 40.4% | 214.6% | -1125.0% | 101.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
52.9%
EPS terminal req.
$2.32
Spread vs growth
-38.9%
5Y implied EPS CAGR
34.0%
EPS terminal req.
$2.81
Spread vs growth
-20.0%
10Y implied EPS CAGR
21.4%
EPS terminal req.
$4.53
Spread vs growth
-7.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+21.9%
Start / end P/E
37.7x → 40.3x
EPS bridge
0.57 → 0.65
Residual
+1.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.